Agenus Inc., an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies, said the FDA accepted the company’s IND filing for AGEN1423—a milestone in its partnership with Gilead that triggered a cash payment of $7.5 million. Agenus is eligible to receive additional milestone payments in 2019 and beyond.   “This marks the first milestones in our collaboration with Gilead,” said Garo Armen, chief executive officer, Agenus...